Prion-like mechanisms in neurodegenerative diseases

Nature Reviews Neuroscience

Volumn 11, Issue 3, 2010, Pages 155-159

  Frost, Bess ^a   Diamond, Marc I ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; COLLAGEN FIBRIL; FIBRILLAR COLLAGEN; MUTANT PROTEIN; POLYGLUTAMINE; PRESENILIN; PRION PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; BIOACCUMULATION; BRAIN REGION; CELL THERAPY; CELL TRANSFER; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DISEASE MODEL; DISEASE TRANSMISSION; ENDOSOME; FRONTOTEMPORAL DEMENTIA; GENE AMPLIFICATION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; INCLUSION BODY MYOSITIS; KURU; LEWY BODY; LYSOSOME; MISSENSE MUTATION; MOLECULAR INTERACTION; NERVE DEGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PHENOTYPE; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; REVIEW; SENILE PLAQUE; VASCULAR AMYLOIDOSIS; VIRUS STRAIN; WILD TYPE;

ALPHA-SYNUCLEIN; AMYLOID BETA-PROTEIN; BRAIN; DISEASE PROGRESSION; HUMANS; NEURODEGENERATIVE DISEASES; PRIONS; PROTEIN CONFORMATION; TAU PROTEINS;

EID: 77249133010     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn2786     Document Type: Review

References (60)

1. Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136-144 (1982).
2. Caughey, B., Race, R. E. & Chesebro, B. Detection of prion protein mRNA in normal and scrapie-infected tissues and cell lines. J. Gen. Virol. 69, 711-716 (1988).
3. Pan, K. M. et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl Acad. Sci. USA 90, 10962-10966 (1993).
4. Prusiner, S. B. Prions. Proc. Natl Acad. Sci. USA 95, 13363-13383 (1998).
5. Williamson, J., Goldman, J. & Marder, K. S. Genetic aspects of Alzheimer disease. Neurologist 15, 80-86 (2009).
6. Armstrong, R. A., Nochlin, D. & Bird, T. D. Neuropathological heterogeneity in Alzheimer's disease: a study of 80 cases using principal components analysis. Neuropathology 20, 31-37 (2000).
7. Chui, H. C., Teng, E. L., Henderson, V. W. & Moy, A. C. Clinical subtypes of dementia of the Alzheimer type. Neurology 35, 1544-1550 (1985).
8. Askanas, V. & Engel, W. K. Inclusion-body myositis: a myodegenerative conformational disorder associated with Aβ, protein misfolding, and proteasome inhibition. Neurology 66, S39-S48 (2006).
9. Glenner, G. G. & Wong, C. W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890 (1984).
10. Goedert, M. et al. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356, 213-227 (2001).
11. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997).
12. Zarranz, J. J. et al. The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173 (2004).
13. Ibanez, P. et al. Causal relation between α-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 1169-1171 (2004).
14. Singleton, A. B. et al. α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841 (2003).
15. Chartier-Harlin, M. C. et al. α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169 (2004).
16. Ironside, J. W., Ritchie, D. L. & Head, M. W. Phenotypic variability in human prion diseases. Neuropathol. Appl. Neurobiol. 31, 565-579 (2005).
17. Wadsworth, J. D. & Collinge, J. Update on human prion disease. Biochim. Biophys. Acta 1772, 598-609 (2007).
18. Hsiao, K. et al. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature 338, 342-345 (1989).
19. Gajdusek, D. C. Unconventional viruses and the origin and disappearance of kuru. Science 197, 943-960 (1977).
20. Prusiner, S. B. Prion diseases and the BSE crisis. Science 278, 245-251 (1997).
21. Bessen, R. A. et al. Non-genetic propagation of strain-specific properties of scrapie prion protein. Nature 375, 698-700 (1995).
22. Telling, G. C. et al. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274, 2079-2082 (1996).
23. Sc molecules with different conformations. Nature Med. 4, 1157-1165 (1998).
24. Legname, G. et al. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc. Natl Acad. Sci. USA 103, 19105-19110 (2006).
25. Tanaka, M., Collins, S. R., Toyama, B. H. & Weissman, J. S. The physical basis of how prion conformations determine strain phenotypes. Nature 442, 585-589 (2006).
26. Toyama, B. H., Kelly, M. J., Gross, J. D. & Weissman, J. S. The structural basis of yeast prion strain variants. Nature 449, 233-237 (2007).
27. Frost, B., Ollesch, J., Wille, H. & Diamond, M. I. Conformational diversity of wild-type Ta u fibrils specified by templated conformation change. J. Biol. Chem. 284, 3546-3551 (2009).
28. Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's β-amyloid fibrils. Science 307, 262-265 (2005).
29. Yonetani, M. et al. Conversion of wild-type α-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J. Biol. Chem. 284, 7940-7950 (2009).
30. 311) forming β structure. Proc. Natl Acad. Sci. USA 97, 5129-5134 (2000).
31. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239-259 (1991).
32. Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L. & Greicius, M. D. Neurodegenerative diseases target large-scale human brain networks. Neuron 62, 42-52 (2009).
33. Hobson, P. & Meara, J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 28, 39-43 (1999).
34. Cudkowicz, M., Qureshi, M. & Shefner, J. Measures and markers in amyotrophic lateral sclerosis. NeuroRx 1, 273-283 (2004).
35. Brown, P., Preece, M. A. & Will, R. G. "Friendly fire" in medicine: hormones, homografts, and Creutzfeldt-Jakob disease. Lancet 340, 24-27 (1992).
36. Beekes, M., McBride, P. A. & Baldauf, E. Cerebral targeting indicates vagal spread of infection in hamsters fed with scrapie. J. Gen. Virol. 79, 601-607 (1998).
37. Fraser, H. Neuronal spread of scrapie agent and targeting of lesions within the retino-tectal pathway. Nature 295, 149-150 (1982).
38. Brandner, S. et al. Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system. Proc. Natl Acad. Sci. USA 93, 13148-13151 (1996).
39. Magalhaes, A. C. et al. Uptake and neuritic transport of scrapie prion protein coincident with infection of neuronal cells. J. Neurosci. 25, 5207-5216 (2005).
40. Fevrier, B. et al. Cells release prions in association with exosomes. Proc. Natl Acad. Sci. USA 101, 9683-9688 (2004).
41. Gousset, K. et al. Prions hijack tunnelling nanotubes for intercellular spread. Nature Cell Biol. 11, 328-336 (2009).
42. Gerdes, H. H. & Carvalho, R. N. Intercellular transfer mediated by tunneling nanotubes. Curr. Opin. Cell Biol. 20, 470-475 (2008).
43. Li, J. Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nature Med. 14, 501-503 (2008).
44. Kordower, J. H., Chu, Y., Hauser, R. A., Olanow, C. W. & Freeman, T. B. Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov. Disord. 23, 2303-2306 (2008).
45. Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Med. 14, 504-506 (2008).
46. Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc. Natl Acad. Sci. USA 106, 13010-13015 (2009).
47. Yang, W., Dunlap, J. R., Andrews, R. B. & Wetzel, R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917 (2002).
48. Lee, H. J. et al. Assembly-dependent endocytosis and clearance of extracellular α-synuclein. Int. J. Biochem. Cell Biol. 40, 1835-1849 (2008).
49. Frost, B., Jacks, R. L. & Diamond, M. I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845-12852 (2009).
50. Ren, P. H. et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nature Cell Biol. 11, 219-225 (2009).
51. Krammer, C. et al. The yeast Sup35NM domain propagates as a prion in mammalian cells. Proc. Natl Acad. Sci. USA 106, 462-467 (2009).
52. Meyer-Luehmann, M. et al. Exogenous induction of cerebral β-amyloidogenesis is governed by agent and host. Science 313, 1781-1784 (2006).
53. Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nature Cell Biol. 11, 909-913 (2009).
54. Werdelin, O. & Ranlov, P. Amyloidosis in mice produced by transplantation of spleen cells from casein-treated mice. Acta Pathol. Microbiol. Scand. 68, 1-18 (1966).
55. Westermark, G. T. & Westermark, P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett. 583, 2685-2690 (2009).
56. Lundmark, K. et al. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc. Natl Acad. Sci. USA 99, 6979-6984 (2002).
57. Mendez, O. E., Shang, J., Jungreis, C. A. & Kaufer, D. I. Diffusion-weighted MRI in Creutzfeldt-Jakob disease: a better diagnostic marker than CSF protein 14-3-3? J. Neuroimaging 13, 147-151 (2003).
58. Asuni, A. A., Boutajangout, A., Quartermain, D. & Sigurdsson, E. M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129 (2007).
59. Masliah, E. et al. Effects of α-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868 (2005).
60. Nekooki-Machida, Y. et al. Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity. Proc. Natl Acad. Sci. USA 106, 9679-9684 (2009).